Cipla surges to record high on earnings
Reuters Market Eye - Shares in Cipla (CIPL.NS) gain as much as 4.06 percent to a record high after the drug maker reported a bigger-than-expected 62 percent surge in July-September net profit.
Despite the surge in share prices, Citigroup says on Tuesday it remains cautious, saying the earnings surprise were mainly driven by the generic version of anti-depressant drug Lexapro, whose exclusivity would tail off in the second half of the fiscal year.
Cipla had earlier given a revenue guidance of up to 12 percent for the current fiscal year, but Citigroup says the company management has now revised its topline growth to 15 percent or above in FY13.
Citigroup adds positives such as better product mix and upside from a weaker rupee appeared factored into estimates and valuations.
The bank raised its target price to 390 rupees from 360 rupees, but retained its 'neutral' rating.
- Tweet this
- Share this
- Digg this
- Boxer Sarita Devi faces action after refusing medal at Asian Games
- Dallas Ebola patient vomited outside apartment on way to hospital
- Loss of smell may be predictor of death in older adults - study
- Billionaire Detroit business leader says "blight is like a cancer"
- Dallas Ebola patient vomited outside apartment on way to hospital |
India could run out of a critical medicine in its free HIV/AIDS drugs programme in three weeks due to bureaucratic bungling, a senior government official said, leaving more than 150,000 sufferers without life-saving drugs for about a month. Full Article